共 50 条
- [31] Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 studyGYNECOLOGIC ONCOLOGY, 2024, 186 : 182 - 190Gonzalez-Martin, AntonioChung, Hyun CheolSaada-Bouzid, EsmaYanez, EduardoSenellart, HeleneCassier, Philippe A.Basu, BristiCorr, Bradley R.Girda, EugeniaDutcus, CorinaOkpara, Chinyere E.Ghori, RaziJin, FanGroisberg, RomanLwin, Zarnie
- [32] Epacadostat plus pembrolizumab in patients with advanced melanoma: Phase 1 and 2 efficacy and safety results from ECHO-202/KEYNOTE-037ANNALS OF ONCOLOGY, 2017, 28Hamid, O.Gajewski, T. F.Frankel, A. E.Bauer, T. M.Olszanski, A. J.Luke, J. J.Balmanoukian, A. S.Schmidt, E. V.Sharkey, B.Maleski, J.Jones, M. J.Gangadhar, T. C.
- [33] Pembrolizumab for patients with advanced prostate adenocarcinoma: Preliminary results from the KEYNOTE-028 studyANNALS OF ONCOLOGY, 2016, 27Hansen, A.Massard, C.Ott, P. A.Haas, N.Lopez, J.Ejadi, S.Wallmark, J.Keam, B.Delord, J-P.Aggarwal, R.Gould, M.Qiu, P.Saraf, S.Keefe, S.Piha-Paul, S. A.
- [34] Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Seiwert, Tanguy Y.Haddad, Robert I.Gupta, ShilpaMehra, RaneeTahara, MakotoBerger, RaananLee, Se-HoonBurtness, BarbaraLe, Dung T.Heath, KarlBlum, AmyDolled-Filhart, MarisaEmancipator, KennethPathiraja, KumuduCheng, Jonathan D.Chow, Laura Q.
- [35] TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib plus pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)-Results from ROC cohort.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Konstantinopoulos, Panagiotis A.Waggoner, Steven E.Vidal, Gregory A.Mita, Monica M.Fleming, Gini F.Holloway, Robert W.Van Le, LindaSachdev, Jasgit C.Chapman-Davis, EloiseColon-Otero, GerardoPenson, Richard T.Matulonis, Ursula A.Kim, Young B.Moore, Kathleen N.Swisher, Elizabeth M.Dezube, Bruce JeffreyWang, Jing Y.Buerstatte, NathanArora, SujataMunster, Pamela N.
- [36] Phase I/I study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent ovarian cancer (KEYNOTE-162).JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Konstantinopoulos, PanagiotisMoore, Kathleen N.Sachdev, Jasgit C.Mita, Monica M.Vinayak, ShavetaSeward, Shelly MarieKarantza, VassilikiAktan, GurselFerguson, AndrewBobilev, DmitriMatulonis, Ursula A.
- [37] Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 StudyJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (07) : 752 - 761O'Malley, David M.Bariani, Giovanni MendoncaCassier, Philippe A.Marabelle, AurelienHansen, Aaron R.Acosta, Ana De JesusMiller, Wilson H., Jr.Safra, TamarItaliano, AntoineMileshkin, LindaXu, LeiJin, FanNorwood, KevinMaio, Michele
- [38] Pembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 studyANNALS OF ONCOLOGY, 2018, 29 : 210 - 210Ueno, M.Chung, H. C.Nagrial, A.Marabelle, A.Kelley, R. K.Xu, L.Mahoney, J.Pruitt, S. K.Oh, D-Y.
- [39] Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 StudyJOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (36) : 4050 - +Hsu, ChiunLee, Se-HoonEjadi, SamuelEven, CarolineCohen, Roger B.Le Tourneau, ChristopheMehnert, Janice M.Algazi, Alainvan Brummelen, Emilie M. J.Saraf, SanatanThanigaimani, PradeepCheng, Jonathan D.Hansen, Aaron R.
- [40] Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 studyANNALS OF ONCOLOGY, 2019, 30 : 908 - 908Grob, J. J.Gonzalez Mendoza, R.Basset-Seguin, N.Vornicova, O.Schachter, J.Joshi, A.Meyer, N.Grange, F.Piulats, J. M.Bauman, J.Zhang, P.Gumuscu, B.Swaby, R. F.Hughes, B. G. M.